ClinicalTrials.gg

Sjogren's Syndrome clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 330 studies for Sjogren's Syndrome across more than 10 countries. 99 are recruiting or about to start. 222 of them are mainly about Sjogren's Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Completed
150
Recruiting
67
Status unknown
36
Not yet recruiting
28
Terminated
19
Active, not recruiting
13

Phase

Phase 2
82
Phase 1
46
Phase 3
28
Phase 4
18
Early Phase 1
13

Where

United States
111
France
58
China
55
Taiwan
31
United Kingdom
27
Brazil
26

Who develops what

Add Sjogren's Syndrome to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 24 programs from 20 companies, 15 with this as their studies’ main aim; 5 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Bristol-Myers Squibb, Innovent Biologics and Novartis here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
deucravacitinibApproved: US 2022 · EU 2023☆ Track2 live phase-3 studies: NCT07791199, NCT05946941Bristol-Myers Squibb
nipocalimabApproved: US 2025 · EU 2025☆ Track1 live phase-3 study: NCT06741969Johnson & Johnson
telitacicept☆ Track1 live phase-3 study: NCT07404865Vor Biopharma
ianalumab☆ Track3 live phase-3 studies: NCT07621809, NCT05985915, NCT05349214Novartis
dazodalibep☆ Track2 live phase-3 studies: NCT06747949, NCT06245408Amgen

The 5 in phase 3 with the nearest primary completion, of 24 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 18 Nov 2026 est.deucravacitinib · Bristol-Myers Squibb · Phase 3 main aimNCT05946941 A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome — primary endpoint: Change from baseline in European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 52 · 774 enrolled
  • 30 Dec 2026 est.Recombinant Human Proteoglycan 4 · Lubris Bio Pty Ltd · Phase 2 main aimNCT07118241 A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE — primary endpoint: To assess the efficacy of rhPRG4 by looking at the frequency of patients attaining complete resolution of total corneal staining with fluorescein (Oxford Scale) at Day 28 · 80 enrolled
  • 4 Feb 2027 est.nipocalimab · Johnson & Johnson · Phase 3 main aimNCT06741969 Nipocalimab in Moderate to Severe Sjogren's Disease — primary endpoint: Change from Baseline in Clinical European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (ClinESSDAI) Score at Week 48 · 655 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Sjogren's Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 2 open · JAK inhibitors 2 open · Calcineurin inhibitors 7

Coming up

26studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger. 9 (13%) take children under 18. 3 (4%) are for women only and 0 (0%) for men only; 11 (16%) take healthy volunteers.

Recruiting studies that take each age, of 67
AgeWomenMen
108 (12%)7 (10%)
1860 (90%)58 (87%)
3064 (96%)61 (91%)
4064 (96%)61 (91%)
5064 (96%)61 (91%)
6564 (96%)61 (91%)
7548 (72%)46 (69%)
8537 (55%)35 (52%)

Across all 330 studies, recruiting or not: 40% stop at 75 or younger and 16% at 65; 12% take children; 9% are for women only and 0% for men only; 18% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Sjogren's Syndrome studies take

Of 26 phase 2 interventional studies under Sjogren's Syndrome, half reached primary completion within 25 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 225 mo17–43 · 26 studies——
Interventional, no phase18 mo10–35 · 44 studies—18 mo10–35 · 39 studies
Observational64 mo21–… · 40 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 330. Browse all 330 → or search them.